

226-104US SEQ LIST.txt  
SEQUENCE LISTING

<110> DUFT, BRADFORD J.  
KOLTERMAN, ORVILLE G.

<120> METHODS FOR TREATING OBESITY

<130> 18528.231

<140> US 08/870,762

<141> 1997-06-06

<160> 25

<170> PatentIn version 3.3

<210> 1

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide construct

<400> 1

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 2

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide construct

<400> 2

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 3

<211> 37

<212> PRT

## 226-104US SEQ LIST.txt

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;400&gt; 3

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

&lt;210&gt; 4

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;400&gt; 4

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Pro Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

&lt;210&gt; 5

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;400&gt; 5

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

## 226-104US SEQ LIST.txt

<210> 6  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<220>  
<221> misc\_feature  
<223> 2,7-Cyclo bridge

<400> 6

Lys Asp Asn Thr Ala Thr Lys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 7  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 7

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35

<210> 8  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 8

Ala Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

## 226-104US SEQ LIST.txt

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 9  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 9

Ser Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 10  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 10

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Pro Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 11  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 11

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu

1 5 226-104US SEQ LIST.txt 15  
10 15  
Val His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 12  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 12

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35

<210> 13  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 13

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Ser Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35

<210> 14  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

## 226-104US SEQ LIST.txt

&lt;400&gt; 14

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

Arg Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35

&lt;210&gt; 15

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;400&gt; 15

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Ile Leu Pro Pro Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35

&lt;210&gt; 16

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;400&gt; 16

Val Thr His Arg Leu Ala Gly Leu Leu Ser Arg Ser Gly Gly Val Val  
1 5 10 15

Lys Asn Asn Phe Val Pro Thr Asn Val Gly Ser Lys Ala Phe  
20 25 30

&lt;210&gt; 17

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

## 226-104US SEQ LIST.txt

<220>  
<221> MISC\_FEATURE  
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Lys, Ala, Ser, or not present

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> Ala, Ser, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (17)..(17)  
<223> Val, Leu, or Ile

<220>  
<221> MISC\_FEATURE  
<222> (18)..(18)  
<223> His or Arg

<220>  
<221> MISC\_FEATURE  
<222> (19)..(19)  
<223> Ser or Thr

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> Ser, Thr, Gln, or Asn

<220>  
<221> MISC\_FEATURE  
<222> (21)..(21)  
<223> Asn, Gln, or His

<220>  
<221> MISC\_FEATURE  
<222> (23)..(23)  
<223> Phe, Leu, or Tyr

<220>  
<221> MISC\_FEATURE  
<222> (26)..(26)  
<223> Ile, Val, Ala, or Leu

<220>  
<221> MISC\_FEATURE  
<222> (29)..(29)

## 226-104US SEQ LIST.txt

<223> Ser, Pro, or Thr

<220>

<221> MISC\_FEATURE

<222> (31)..(31)

<223> Asn, Asp, or Gln

<400> 17

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu  
1 5 10 15

xaa xaa xaa xaa xaa Asn xaa Gly Pro xaa Leu Pro xaa Thr xaa Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 18

<211> 37

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic peptide construct

<220>

<221> MISC\_FEATURE

<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Lys, Ala, Ser, or not present

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Variable amino acid

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> Variable amino acid

<220>

<221> MISC\_FEATURE

<222> (13)..(13)

<223> Ala, Ser, or Thr

<220>

<221> MISC\_FEATURE

<222> (17)..(17)

<223> Val, Leu, or Ile

<220>

<221> MISC\_FEATURE

<222> (18)..(18)



## 226-104US SEQ LIST.txt

&lt;223&gt; His or Arg

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (19)..(19)

&lt;223&gt; Ser or Thr

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (20)..(20)

&lt;223&gt; Ser, Thr, Gln, or Asn

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (21)..(21)

&lt;223&gt; Asn, Gln, or His

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (23)..(23)

&lt;223&gt; Phe, Leu, or Tyr

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (26)..(26)

&lt;223&gt; Ile, Val, Ala, or Leu

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (28)..(28)

&lt;223&gt; Ser, Pro, Leu, Ile or Thr

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (31)..(31)

&lt;223&gt; Asn, Asp, or Gln

&lt;400&gt; 18

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Xaa Pro Thr Xaa Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

&lt;210&gt; 19

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic peptide construct

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino,  
Page 9

226-104US SEQ LIST.txt  
arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Lys, Ala, Ser, or not present

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> Ala, Ser, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (17)..(17)  
<223> Val, Leu, or Ile

<220>  
<221> MISC\_FEATURE  
<222> (18)..(18)  
<223> His or Arg

<220>  
<221> MISC\_FEATURE  
<222> (19)..(19)  
<223> Ser or Thr

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> Ser, Thr, Gln, or Asn

<220>  
<221> MISC\_FEATURE  
<222> (21)..(21)  
<223> Asn, Gln, or His

<220>  
<221> MISC\_FEATURE  
<222> (23)..(23)  
<223> Phe, Leu, or Tyr

<220>  
<221> MISC\_FEATURE  
<222> (25)..(25)  
<223> Ala or Pro

<220>  
<221> MISC\_FEATURE  
<222> (26)..(26)  
<223> Ile, Val, Ala, or Leu

<220>

## 226-104US SEQ LIST.txt

<221> MISC\_FEATURE  
<222> (31)..(31)  
<223> Asn, Asp, or Gln

<400> 19

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Xaa Xaa Leu Pro Pro Thr Xaa Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 20  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<220>  
<221> MISC\_FEATURE  
<223> c-term may be amino, alkylamino, dialkylamino, cycloalkylamino,  
arylamino, aralkylamino, alkyloxy, aryloxy, or aralkyloxy

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Lys, Ala, Ser, or not present

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> Ala, Ser, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (17)..(17)  
<223> Val, Leu, or Ile

<220>  
<221> MISC\_FEATURE  
<222> (18)..(18)  
<223> His or Arg

<220>

## 226-104US SEQ LIST.txt

<221> MISC\_FEATURE  
<222> (19)..(19)  
<223> Ser or Thr

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> Ser, Thr, Gln, or Asn

<220>  
<221> MISC\_FEATURE  
<222> (21)..(21)  
<223> Asn, Gln, or His

<220>  
<221> MISC\_FEATURE  
<222> (23)..(23)  
<223> Phe, Leu, or Tyr

<220>  
<221> MISC\_FEATURE  
<222> (26)..(26)  
<223> Ile, Val, Ala, or Leu

<220>  
<221> MISC\_FEATURE  
<222> (31)..(31)  
<223> Asn, Asp, or Gln

<400> 20

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Pro Xaa Leu Pro Pro Thr Xaa Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 21  
<211> 37  
<212> PRT  
<213> Rattus norvegicus

<220>  
<221> misc\_feature  
<223> 2,7-Cylco bridge

<400> 21

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val  
20 25 30

## 226-104US SEQ LIST.txt

Gly Ser Asn Thr Tyr  
35

<210> 22  
<211> 37  
<212> PRT  
<213> Homo sapiens

<400> 22

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 23  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<220>  
<221> MISC\_FEATURE  
<223> c-term may be hydroxy, amino, alkylamino, dialkylamino,  
cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy, or  
aralkyloxy

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Lys, Ser, Ala, acetylated Lys, or not present

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Variable amino acid

<220>  
<221> MISC\_FEATURE  
<222> (13)..(13)  
<223> Ala, Ser, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (17)..(17)  
<223> Val, Leu, or Ile

## 226-104US SEQ LIST.txt

<220>  
<221> MISC\_FEATURE  
<222> (18)..(18)  
<223> His or Arg

<220>  
<221> MISC\_FEATURE  
<222> (19)..(19)  
<223> Ser or Thr

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> Ser, Thr, Gln, or Asn

<220>  
<221> MISC\_FEATURE  
<222> (21)..(21)  
<223> Asn, Gln, or His

<220>  
<221> MISC\_FEATURE  
<222> (23)..(23)  
<223> Phe, Leu, or Tyr

<220>  
<221> MISC\_FEATURE  
<222> (25)..(25)  
<223> Ala or Pro

<220>  
<221> MISC\_FEATURE  
<222> (26)..(26)  
<223> Ile, Val, Ala, or Leu

<220>  
<221> MISC\_FEATURE  
<222> (28)..(28)  
<223> Ser, Pro, Leu, Ile, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (29)..(29)  
<223> Ser, Pro, or Thr

<220>  
<221> MISC\_FEATURE  
<222> (31)..(31)  
<223> Asn, Asp, or Gln

<400> 23

Xaa Xaa Asn Thr Ala Thr Xaa Ala Thr Gln Arg Leu Xaa Asn Phe Leu  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Asn Xaa Gly Xaa Xaa Leu Xaa Xaa Thr Xaa Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

## 226-104US SEQ LIST.txt

<210> 24  
<211> 37  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> Arg is a D amino acid residue

<400> 24

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu  
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val  
20 25 30

Gly Ser Asn Thr Tyr  
35

<210> 25  
<211> 36  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic peptide construct

<400> 25

Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu Val  
1 5 10 15

His Ser Ser Asn Asn Phe Gly Pro Val Leu Pro Pro Thr Asn Val Gly  
20 25 30

Ser Asn Thr Tyr  
35